🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

START A and B, Wang et al , DKSG and now Hypo Ig all showing no difference in morbidity , LRR , DFS or OS with 3 weeks RNI #bcsm ARRO

Important read on INTERLACE . It brings up issues of modern trial with systemic agent but still using older RT techniques which questions whether gain is real #gynsm ⁦DrKamrava⁩ ⁦Matthew Harkenrider, MD⁩ ⁦Ann Klopp⁩ ⁦Emma Fields, MD⁩ ijgc.bmj.com/content/early/…

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial sciencedirect.com/science/articl…

Interactive sessions with Rad Onc trainees #ranzcr2024 RANZCR Ziad Thotathil Prostate_doc ARRO Andrew Keller AHN

2D to 3D brachytherapy transition with workshops ⁦DrKamrava⁩ ⁦American Brachy⁩ ⁦Scott Glaser⁩ ⁦Ann Klopp⁩ ⁦Andrew Keller⁩ ⁦Hima Bindu Musunuru⁩ ⁦AHN⁩ sciencedirect.com/science/articl…

Results from our phase II trial of brain MRI surveillance in stage IV breast cancer now out in SNO academic.oup.com/neuro-oncology… By 6 months, about 25% of patients developed brain mets regardless of subtype OncoAlert Thank you Florida Breast Cancer Foundation for the support!

#GU25: Key #bladdercancer presentations (in my opinion)- highlights and summary coming after the conference from AdventHealth Central Florida #cancer Institute- please note OncoAlert LARVOL OncLive.com GU Oncology Now SWOG Cancer Research Network Research To Practice PeerView Doximity

GOG 258 chemo RT better than chemo for p53 wild type while PORTEC 3 chemo RT better than RT for p53 abnormal ; function of lack of pretreatment stratification , small sample size or other variables DrKamrava Scott Glaser Ann Klopp Andrew Keller #gynsm

Metastasis directed therapy improves outcome in all oligo metastatic prostate cancer. Compliments to the Wolverine meta-analysis Team🏆 ASCO #GU25 Chad Tang, MD

These #HealioInnovators nominees are at the top of their game in #HealthEquity William Dale, MD, PhD, FASCO Nathalie Mckenzie, MD MSPH Maria Borrero MD Shearwood McClelland III, M.D. Nadine J. Barrett, PhD, MA., MS Ana I. Velázquez Mañana, MD, MSc, FASCO Vote here: bit.ly/3FcaQAo

🚀 Ready to elevate your expertise? Register now for #ABSBrachy25 & join key thought leaders in Nashville! Don't miss the chance to connect, learn, and innovate in the field of #brachytherapy.🏙️ #Brachytherapy bit.ly/4iCD1ae @andrewfarach marisa kollmeier DrKamrava

First hybrid brachytherapy in Guatemala American Brachy DrKamrava Andrew Keller Scott Glaser

Danish data with longer follow up shows no difference in lymphedema or LRR with RNI hypofractionation Icro Meattini Erin Gillespie, MD MPH Scott Glaser Andrew Keller #estro2025

Best #ESTRO2025 abstract for EMBRACE2 showing excellent locoregional control and significantly reduced morbidity compared to embrace 1 with tighter dose constraints with higher use of hybrid applicator ( new standard ) DrKamrava Scott Glaser Andrew Keller American Brachy

PORTEC 4a results . High risk benefits from EBRT ( only 25% had LND) and low risk has small but non inferior difference in vaginal recurrence with VBT DrKamrava Andrew Keller

Confirms and establishes new SOC. First one comparing SRS to HAWBRT showing less symptom burden and better functional outcome with SRS Andrew Keller ARRO ACROresident

From #ASCO25: Kamran Ahmed, MD (Kamran Ahmed) highlights results from a phase II trial of SBRT + atezolizumab in metastatic cervical cancer, showing promising responses even in PD-L1 negative tumors. #MoffittASCO25

Adaptive brachy - why and how ? Winship Grand Rounds: April 23, 2025 - Sushil Beriwal, MD youtu.be/WH0CZ0IBne8?si… via YouTube American Brachy DrKamrava Andrew Keller ARRO Emma Fields, MD Scott Glaser Reshma Jagsi Jill Remick

More to learn from molecular based treatment for endometrial cancer DrKamrava

TDABC - important concept but not routinely calculated in health care. What is not measured can’t be improved Andrew Keller